Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain – A GEICO study

被引：0

作者：

Alfonso Yubero

Aranzazu Barquín

Purificación Estévez

Bella Pajares

Luisa Sánchez

Piedad Reche

Jesús Alarcón

Julia Calzas

Lydia Gaba

José Fuentes

Ana Santaballa

Carmen Salvador

Luis Manso

Ana Herrero

Álvaro Taus

Raúl Márquez

Julia Madani

María Merino

Gloria Marquina

Victoria Casado

Manuel Constenla

María Gutiérrez

Alba Dosil

Antonio González-Martín

机构：

[1] Hospital Clínico Universitario Lozano Blesa,Medical Oncology

[2] Centro Integral Oncológico Clara Campal,Medical Oncology

[3] Hospital Universitario Virgen del Rocío,Medical Oncology

[4] Hospital Universitario Virgen de la Victoria,Medical Oncology

[5] Clínica Universidad de Navarra,Medical Oncology

[6] Hospital Universitario Torrecárdenas,Medical Oncology

[7] Hospital Universitario Son Espases,Medical Oncology

[8] Hospital Universitario de Fuenlabrada,Medical Oncology

[9] Hospital Clínic de Barcelona,Department of Medical Oncology, Translational Genomics and Targeted Therapeutics in Solid Tumors

[10] Institut D’Investigacions Biomèdiques August Pi I Sunyer (Idibaps),Medical Oncology

[11] Hospital Universitario Virgen de Valme,Medical Oncology

[12] Hospital Universitario i Politècnic la Fe,Medical Oncology

[13] Hospital Lluís Alcanyís de Xàtiva,Medical Oncology

[14] Hospital Universitario 12 de Octubre,Medical Oncology

[15] Hospital Universitario Miguel Servet,Medical Oncology

[16] Hospital del Mar,Medical Oncology

[17] MD Anderson Cancer Center,Medical Oncology

[18] Hospital Universitario San Jorge,Medical Oncology

[19] Hospital Universitario Infanta Sofía,Medical Oncology

[20] Hospital Clínico San Carlos,Medical Oncology

[21] Fundación Jiménez Díaz,Medical Oncology

[22] Complejo Hospitalario Universitario de Pontevedra,Medical Oncology

[23] Hospital Universitario Txagorritxu,undefined

[24] Clovis Oncology ,undefined

[25] Centre for Applied Medical Research,undefined

来源：

BMC Cancer | / 22卷

关键词：

Rucaparib; Recurrent ovarian cancer; Maintenance; Treatment; PARP inhibitor;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 19 条

[1] Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain - A GEICO study
Yubero, Alfonso
Barquin, Aranzazu
Estevez, Purificacion
Pajares, Bella
Sanchez, Luisa
Reche, Piedad
Alarcon, Jesus
Calzas, Julia
Gaba, Lydia
Fuentes, Jose
Santaballa, Ana
Salvador, Carmen
Manso, Luis
Herrero, Ana
Taus, Alvaro
Marquez, Raul
Madani, Julia
Merino, Maria
Marquina, Gloria
Casado, Victoria
Constenla, Manuel
Gutierrez, Maria
Dosil, Alba
Gonzalez-Martin, Antonio
BMC CANCER, 2022, 22 (01)
[2] Rucaparib for PARP inhibitor-pretreated ovarian cancer: A GEICO retrospective subgroup analysis from the Spanish Rucaparib Access Program
Yubero, Alfonso
Estevez, Purificacion
Barquin, Aranzazu
Sanchez, Luisa
Santaballa, Ana
Pajares, Bella
Reche, Piedad
Salvador, Carmen
Manso, Luis
Marquez, Raul
Gonzalez-Martin, Antonio
GYNECOLOGIC ONCOLOGY REPORTS, 2023, 48
[3] Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme
Cueva, Juan F.
Palacio, Isabel
Churruca, Cristina
Herrero, Ana
Pardo, Beatriz
Constenla, Manuel
Santaballa, Ana
Manso, Luis
Estevez, Purificacin
Maximiano, Constanza
Legeren, Marta
Marquina, Gloria
de Juan, Ana
Quindos, Maria
Sanchez, Luisa
Barquin, Arantzazu
Fernandez, Isaura
Martin, Cristina
Juarez, Asuncin
Martin, Teresa
Garcia, Yolanda
Yubero, Alfonso
Gallego, Alejandro
Bueno, Alejandro Martinez
Guerra, Eva
Gonzalez-Martin, Antonio
EUROPEAN JOURNAL OF CANCER, 2023, 182 : 3 - 14
[4] Real-World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10
Drew, Yvette
Kristeleit, Rebecca S.
Oaknin, Ana
Ray-Coquard, Isabelle
Haris, Noor Md.
Swisher, Elizabeth M.
ONCOLOGIST, 2020, 25 (01) : E109 - E119
[5] Real-world experience of pembrolizumab and lenvatinib in recurrent endometrial cancer: A multicenter study in Korea
Kim, Junhwan
Noh, Joseph J.
Lee, Tae Kyoung
Kim, Se Ik
Lee, Jung-Yun
Lee, Jeong-Won
Kim, Jae-Weon
GYNECOLOGIC ONCOLOGY, 2022, 165 (02) : 369 - 375
[6] A real-world study of PARP inhibitors in 75 patients with platinum-sensitive recurrent ovarian cancer from China
Chen, Jinghong
Zhang, Mengpei
Li, Kemin
Duan, Yuanqiong
Lin, Xiaojuan
Zhong, Lan
Li, Qintong
Yin, Rutie
FRONTIERS IN ONCOLOGY, 2024, 13
[7] Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2
Konecny, Gottfried E.
Oza, Amit M.
Tinker, Anna, V
Oaknin, Ana
Shapira-Frommer, Ronnie
Ray-Coquard, Isabelle
Aghajanian, Carol
Coleman, Robert L.
O'Malley, David M.
Leary, Alexandra
Chen, Lee-may
Provencher, Diane
Ma, Ling
Brenton, James D.
Castro, Cesar
Green, Michelle
Simmons, Andrew D.
Beltman, Jeri
Harding, Thomas
Lin, Kevin K.
Goble, Sandra
Maloney, Lara
Kristeleit, Rebecca S.
McNeish, Iain A.
Swisher, Elizabeth M.
Xiao, Jim J.
GYNECOLOGIC ONCOLOGY, 2021, 161 (03) : 668 - 675
[8] A real-world study on characteristics, treatments and outcomes in US patients with advanced stage ovarian cancer
Beachler, Daniel C.
Lamy, Francois-Xavier
Russo, Leo
Taylor, Devon H.
Dinh, Jade
Yin, Ruihua
Jamal-Allial, Aziza
Dychter, Samuel
Lanes, Stephan
Verpillat, Patrice
JOURNAL OF OVARIAN RESEARCH, 2020, 13 (01)
[9] Unmet clinical needs, burden of disease and treatment patterns in hidradenitis suppurativa: Real-world experience from Spain
Vilarrasa, Eva
Molina-Leyva, Alejandro
Martin, Victor
Coak, Emily
Truman, Isabel
Wallinger, Hayley
Richardson, Craig
Martorell, Antonio
JEADV CLINICAL PRACTICE, 2024, 3 (01): : 347 - 357
[10] Real-World Management of Trabectedin/Pegylated Liposomal Doxorubicin in Platinum-Sensitive Recurrent Ovarian Cancer Patients A National Survey
Ferrandina, Gabriella
Amadio, Giulia
Paris, Ida
Distefano, Mariagrazia
Palluzzi, Eleonora
de Vincenzo, Rosa
Ricci, Caterina
Scambia, Giovanni
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 (06) : 1130 - 1137

← 1 2 →